Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.63 |
| ▸ | JAK1 | P23458 | 5/20 | 0.58 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30410358 | 0.82 | JAK1 (0.55) | NUDT1JAK1EGLN2CHEK1AKT1 | |
| SCHEMBL32664865 | 0.81 | NUDT1 (0.39) | NUDT1JAK1EGLN2CHEK1AKT1 | |
| SCHEMBL2144054 | 0.78 | NUDT1 (1.00) | NUDT1JAK1EGLN2JAK3CHEK1 | |
| SCHEMBL3601961 | 0.76 | NUDT1 (0.78) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL18202876 | 0.75 | CHEK1 (0.38) | NUDT1JAK1CHEK1AKT1AKT2 | |
| SCHEMBL3200526 | 0.75 | NUDT1 (0.76) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL25646677 | 0.74 | LRRK2 (0.40) | NUDT1JAK1 | |
| SCHEMBL2363033 | 0.74 | NUDT1 (0.73) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL22499606 | 0.74 | NUDT1 (0.73) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL2250300 | 0.74 | NUDT1 (0.73) | NUDT1JAK1EGLN2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| CN-111320624-B | Triazolopyridine and imidazopyridine compounds, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-111320624-A | Triazolopyridine and imidazopyridine compounds, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2020-06-23 | — | — | CN | disclosed |
| US-10174036-B2 | Substituted pyrazoles as JAK inhibitors | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| WO-2016173484-A1 | JAK INHIBITORS | 南京明德新药研发股份有限公司 | 2016-11-03 | — | — | WO | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-9012633-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2217578-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174036-B2 | Substituted pyrazoles as JAK inhibitors | JAK1, JAK2, JAK3 | NUDT1 2706/4885JAK1 1/4885EGLN2 1311/4885 |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | NUDT1 2497/4885JAK1 14/4885EGLN2 3693/4885 |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | NUDT1 1340/4885JAK1 1378/4885EGLN2 3685/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | NUDT1 2497/4885JAK1 14/4885EGLN2 3693/4885 |
| US-20180179209-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | NUDT1 3577/4885JAK1 2/4885EGLN2 761/4885 |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | NUDT1 2497/4885JAK1 14/4885EGLN2 3693/4885 |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | NUDT1 2497/4885JAK1 14/4885EGLN2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.